Louise Mercer, Abhishek Abhishek, Akhila Kavirayani, Alison Ahmed, Alan Davidson, Amy Foulkes, Claire Jones, Clare Nash, Emily Rose-Parfitt, Emmandeep Dhillon, Genevieve Zabate, Helen Twohig, Hope De Vere, Jennifer Scott, John Reynolds, Julia Holmes, Karen Hartley, Kishore Warrier, Kataryzna Nowak, Kate Parsons, Katie Bechman, Lisa Bray, Madura Adikari, Natasha Wood, Nicola Faithfull, Nicola Gullick, Pratyasha Saha, Rebecca Heaton, Samundeeswari Deepak, Samantha Hider, Sameena Khalid, Sanaa Suleiman Said, Sarah Ryan, Stuart Kyle, Subhra Raghuvanshi, Su-Yin Tan, Vinay Shivamurthy, James Galloway
{"title":"传统合成改变病情抗风湿药物的处方和监测：英国风湿病学会指南范围。","authors":"Louise Mercer, Abhishek Abhishek, Akhila Kavirayani, Alison Ahmed, Alan Davidson, Amy Foulkes, Claire Jones, Clare Nash, Emily Rose-Parfitt, Emmandeep Dhillon, Genevieve Zabate, Helen Twohig, Hope De Vere, Jennifer Scott, John Reynolds, Julia Holmes, Karen Hartley, Kishore Warrier, Kataryzna Nowak, Kate Parsons, Katie Bechman, Lisa Bray, Madura Adikari, Natasha Wood, Nicola Faithfull, Nicola Gullick, Pratyasha Saha, Rebecca Heaton, Samundeeswari Deepak, Samantha Hider, Sameena Khalid, Sanaa Suleiman Said, Sarah Ryan, Stuart Kyle, Subhra Raghuvanshi, Su-Yin Tan, Vinay Shivamurthy, James Galloway","doi":"10.1093/rap/rkae077","DOIUrl":null,"url":null,"abstract":"<p><p>This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology's 'Creating clinical guidelines: our protocol', updated 2023.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"8 3","pages":"rkae077"},"PeriodicalIF":2.1000,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239329/pdf/","citationCount":"0","resultStr":"{\"title\":\"The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope.\",\"authors\":\"Louise Mercer, Abhishek Abhishek, Akhila Kavirayani, Alison Ahmed, Alan Davidson, Amy Foulkes, Claire Jones, Clare Nash, Emily Rose-Parfitt, Emmandeep Dhillon, Genevieve Zabate, Helen Twohig, Hope De Vere, Jennifer Scott, John Reynolds, Julia Holmes, Karen Hartley, Kishore Warrier, Kataryzna Nowak, Kate Parsons, Katie Bechman, Lisa Bray, Madura Adikari, Natasha Wood, Nicola Faithfull, Nicola Gullick, Pratyasha Saha, Rebecca Heaton, Samundeeswari Deepak, Samantha Hider, Sameena Khalid, Sanaa Suleiman Said, Sarah Ryan, Stuart Kyle, Subhra Raghuvanshi, Su-Yin Tan, Vinay Shivamurthy, James Galloway\",\"doi\":\"10.1093/rap/rkae077\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology's 'Creating clinical guidelines: our protocol', updated 2023.</p>\",\"PeriodicalId\":21350,\"journal\":{\"name\":\"Rheumatology Advances in Practice\",\"volume\":\"8 3\",\"pages\":\"rkae077\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-07-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239329/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rheumatology Advances in Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/rap/rkae077\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology Advances in Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/rap/rkae077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope.
This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology's 'Creating clinical guidelines: our protocol', updated 2023.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
